AV-380 Study for Cancer Patients with Cachexia

This study looks at AV-380, a new treatment for patients with metastatic cancer (cancer that has spread) and cachexia (a condition causing severe weight loss and muscle wasting). AV-380 is a type of medicine called a monoclonal antibody, which can help by targeting substances in the body that contribute to cachexia. The study will check the safety and how the body processes AV-380.

• Participation: You must be at least 18 years old with certain types of cancer and a life expectancy of at least 3 months.
• Requirements: You need to have lost weight recently due to cachexia and should not have certain other serious health issues like heart disease or untreated brain cancer.
• Risks: Possible side effects; however, the study will monitor your health closely.

If you have been diagnosed with metastatic colorectal or pancreatic cancer, and you're dealing with cachexia, this study might be an opportunity for you to try a new treatment. Remember, participation is voluntary, and you can discuss this with your doctor to see if it's right for you.